Achillion Pharma (ACHN) Reports Q3 Loss of $0.15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Leerink Maintains Achillion Pharma (ACHN) at 'Market Perform'; Says MAD Study Questions Raised
November 3, 2016 11:55 AM EDTLeerink affirms Achillion Pharma (NASDAQ: ACHN) at Market Perform following Q3 results and update issued earlier Thursday.
The firm commented today: We believe today's stock weakness is related to caution due to ACHN's disclosure of two cases of liver enzyme elevations in the ongoing multiple ascending dose (MAD) Phase I study of ACH-4471. This update was mentioned... More
Achillion Pharmaceuticals (ACHN) Sell Rating Reiterated at Chardan Capital Markets Amid ACH-4471 Risks
November 3, 2016 11:16 AM EDTChardan Capital Markets analyst Madhu Kumar reiterated a Sell rating and $5 price target on Achillion Pharmaceuticals (NASDAQ: ACHN) saying ACH-4471 liver signals and developmental delays pose risks.
Kumar commented, "This morning, Achillion Pharmaceuticals (Sell) announced 3Q16 earnings results and updates on clinical... More
Achillion Pharma (ACHN) Announces Two Side Effects Observed in MAD Study
November 3, 2016 10:20 AM EDTAchillion Pharma (NASDAQ: ACHN) posted the following with its Q3 press release on Thursday:
Phase I Clinical... More
